Search Jim Cramer's Mad Money trading recommendations using our exclusive Mad Money Stock Screener and watch Jim Cramer's Mad Money Post Game video exclusively on TheStreet.com.


NEW YORK ( TheStreet) -- "Good things can happen to bad markets," Jim Cramer announced to the viewers of his "Mad Money" TV show Friday, as he outlined his game plan for next week's trading action.

Cramer said investors need to pay attention to the results of a few key companies for a read on the health of the overall economy.

Starting on Monday, Cramer said that Tiffany ( TIF) will be the stock to watch. He said the company has a lot of Japanese exposure and he wants to see if the market still punishes the stock, which is already down big since the crisis began.

On Tuesday, Cramer said Dollar General ( DG) will offer a read on the health of the consumer, while drugstore Walgreens ( WAG) will offer insight into its battle to take market share from ailing competitors.

Also on Tuesday Cramer will be at the CTIA Wireless Conference in Orlando, with all the latest news on the mobile smart phone revolution.

For Wednesday, General Mills ( GIS) will provide an update on higher food prices, and whether the company can sustain its margins. Paychex ( PAYX) will provide the real story on the job front, while ConocoPhillips ( COP) will update shareholders on the real situation with oil prices.

Then on Thursday, Cramer said Best Buy ( BBY) and Research In Motion ( RIMM) will report. Cramer said he's given up on both these names, but feels that Oracle ( ORCL), a stock which he owns for his charitable trust, Action Alerts PLUS , is a buy given its low multiple.

Cramer said he'll also be watching Finish Line ( FINL), but doesn't see a reason to own the stock after Nike ( NIKE) disappointed.

Finally on Friday, the Michigan consumer survey will offer a new take on consumer confidence. Cramer said this report will be worth paying attention to.

Speculative Medical Device Play

For "Speculation Friday," Cramer once again looked towards the medical device makers for a safe place to speculate. He said these stocks are primarily domestic, with little international exposure, have no generic competition like the drug stocks, and have found favor in Washington.

Among the group, Cramer singles out Heartware ( HTWR) as his favorite. He said that Heartware makes devices to help those waiting for heart transplants, and with 5 million people in the U.S. suffering from heart disease, the market opportunity is growing.

Heartware is waiting for FDA approval for its lastest assistive device, a device that's already been deemed superior in Europe, with a 90% survival rate versus only 78% for the competing device made by Thoratec ( THOR), of which Cramer is not a fan. Cramer said the Heartware device is clearly superior, with a faster surgery, faster recover and fewer complications.

Cramer was also a fan of Heartware gaining approval for "destination therapies," devices that forgo the need for a transplant altogether. Approval for destination therapies is expected in 2013.

Shares of Heartware are $15 off their $99 high, and Cramer said that makes this speculative name a steal.

A Lot to Like

Continuing with "Speculation Friday," Cramer also highlighted Tornier ( TRNX), a little known orthopedic company that makes implants for extremities such as shoulders, feet, wrists and ankles. Tornier came public last month at $18 a share, and since then, Cramer said investors haven't missed much.

But there's a lot to like about Tornier, said Cramer. The company pretty much dominates the markets in which it competes since many of the bigger players have deemed extremities too small to be profitable. Tornier is expected to introduce a whopping 19 new products in 2011, helping the company reach profitability by 2012.

Cramer said Tornier is interesting as a speculation now, before its profitable, because shares trade at just 2.5 times sales. Based on recent analyst estimates, the value of Tornier's different businesses values the company between $23 and $25 a share. Given its many new product introductions, and its expansion into China, South America and Japan, Cramer said investors shouldn't wait for Tornier to break even.

Advanced Diabetes Treatments

Rounding out Cramer's "Speculation Friday," features, Cramer dove into treating diabetes which affects 8% of all Americans at a cost of $116 billion a year. The diabetes epidemic is expected to grow to 25% of the U.S. population by 2024, thanks to the uncontrolled growth of obesity in our country.

Cramer said DexCom ( DXCM) and Insulet ( PODD), have the potential to change the way diabetes is treated over the next few years.

DexCom is leading the way in constant insulin monitoring devices. Unlike traditional finger pricks, which only monitor four times a day, DexCom's devices provides a constant stream of insulin levels. The company is expected to have $122 million in sales by 2012 and is growing at a 30% rate.

Insulet is leading the charge in insulin pumps, that deliver insulin to the body automatically, instead of relying on the patient to inject themselves. Insulet is waiting on FDA approval for it's latest unit, which is one-third smaller and costs a third less to manufacture.

However the most exciting prospects are when DexCom and Insulet's products are combined. DexCom's monitor alongside Insulet's pump provides essentially an artificial pancreas, which regulates its own insulin levels without patient intervention.

Cramer said the prospects for this new combined therapy could revolutionize the way diabetes is treated going forward, which is why these tow companies are the perfect speculation.

Lightning Round

Cramer was bullish on Starbucks ( SBUX), Schlumberger ( SLB), Limelight Networks ( LLNW) and Pitney Bowes ( PBI).

He was bearish on Honda Motor ( HMC), Agilent Technologies ( A), Molycorp ( MCP) and Skechers USA ( SKX).

Closing Comments

In his "No Huddle Offense" segment, Cramer sounded off against his critics, who called him reckless for focusing on the hope of a Japanese rebuilding rather than the fear of a potential nuclear catastrophe.

Cramer said making money in the markets is all about buying the right stocks, at the right time. He said the bears have proven that there's no money to be made by panicking, but staying the course actually makes money. He said sometimes the situation can actually get better, which is why investors can't always listen to the naysayers.

--Written by Scott Rutt in Washington, D.C.

To contact the writer of this article, click here: Scott Rutt.

To follow the writer on Twitter, go to http://twitter.com/scottrutt.

To submit a news tip, send an email to: tips@thestreet.com.

To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.

Want more Cramer? Check out Jim's rules and commandments for investing from his latest book by clicking here.

For more of Cramer's insights during the Lightning Round, click here .
At the time of publication, Cramer was long Oracle.

Jim Cramer, host of the CNBC television program "Mad Money," is a Markets Commentator for TheStreet.com, Inc., and CNBC, and a director and co-founder of TheStreet.com. All opinions expressed by Mr. Cramer on "Mad Money" are his own and do not reflect the opinions of TheStreet.com or its affiliates, or CNBC, NBC UNIVERSAL or their parent company or affiliates. Mr. Cramer's opinions are based upon information he considers to be reliable, but neither TheStreet.com, nor CNBC, nor either of their affiliates and/or subsidiaries warrant its completeness or accuracy, and it should not be relied upon as such. Mr. Cramer's statements are based on his opinions at the time statements are made, and are subject to change without notice. No part of Mr. Cramer's compensation from CNBC or TheStreet.com is related to the specific opinions expressed by him on "Mad Money."

None of the information contained in "Mad Money" constitutes a recommendation by Mr. Cramer, TheStreet.com or CNBC that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the program. Mr. Cramer's past results are not necessarily indicative of future performance. Neither Mr. Cramer, nor TheStreet.com, nor CNBC guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the program. The strategy or investments discussed may fluctuate in price or value and you may get back less than you invested. Before acting on any information contained in the program, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.

Some of the stocks mentioned by Mr. Cramer on "Mad Money" are held in Mr. Cramer's Action Alerts PLUS Portfolio. When that is the case, appropriate disclosure is made on the program and in the "Mad Money" recap available on TheStreet.com. The Action Alerts PLUS Portfolio contains all of Mr. Cramer's personal investments in publicly-traded equity securities only, and does not include any mutual fund holdings or other institutionally managed assets, private equity investments, or his holdings in TheStreet.com, Inc. Since March 2005, the Action Alerts PLUS Portfolio has been held by a Trust, the realized profits from which have been pledged to charity. Mr. Cramer retains full investment discretion with respect to all securities contained in the Trust. Mr. Cramer is subject to certain trading restrictions, and must hold all securities in the Action Alerts PLUS Portfolio for at least one month, and is not permitted to buy or sell any security he has spoken about on television or on his radio program for five days following the broadcast.

If you liked this article you might like

Stryker and Smith & Nephew Are the Stars to Watch in Medtech's 2015 Merger Dance

Stryker and Smith & Nephew Are the Stars to Watch in Medtech's 2015 Merger Dance

5 Stocks Ready for Breakouts: MediWound and More

5 Stocks Ready for Breakouts: MediWound and More

Tornier (TRNX) Stock Soars Today After Acquiring Wright Medical Group (WMGI)

Tornier (TRNX) Stock Soars Today After Acquiring Wright Medical Group (WMGI)

Wright Medical, Tornier to Combine in $3.3 Billion Deal

Wright Medical, Tornier to Combine in $3.3 Billion Deal